- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03561103
Impact of Representative Payee Services on ART Adherence Among Marginalized People Living With HIV/AIDS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Marginalized populations, including those who are unstably housed and have mental health or substance use disorders, demonstrate alarming rates of disparities in the incidence of new HIV infections and treatment outcomes. These populations have HIV viral suppression rates as low as 13% and mortality 3 to 5 times higher than people living with HIV/AIDS (PLWHA) who have stable housing. Economic disadvantage can contribute to poor medication adherence and clinical outcomes through limited social resources, repeated cycles of housing instability, high levels of stress caused by financial insecurity, and lack of resources to cope with these demands. While the remediation of poverty on a broad scale is not on the near horizon, addressing factors that result from economic disadvantage and limit adherence is feasible and achievable. The investigators aim to understand whether providing financial management to marginalized PLWHA can improve their financial and housing stability, and in turn, antiretroviral therapy treatment adherence and rates of viral suppression.
Representative payee is a structural intervention that provides financial management to marginalized individuals, which has already shown promise in helping marginalized populations achieve undetectable viral loads. Structural interventions aim to alter social, political, or economic contexts in order to improve health outcomes rather than focusing on proximal health behaviors (14). "rep payee" is a Social Security Administration (SSA) policy whereby an organization is appointed to serve as a money manager for vulnerable individuals who receive SSA benefits. The client and their physician complete a request for determination of a representative payee, and once authorized bu SSA, the rep payee establishes a checking account for the client into which SSA entitlements are directly deposited. The client does not have direct access to the account. The rep payee pays the client's bills, which improves regular payment of rent and utilities, and then disburses expendable funds to the client.
In a pilot study examining associations between our "Client-Centered rep payee" services and viral load, it was found that only 7 of 18 participants had suppressed viral loads (SVL) at baseline, but 16 of the 18 had SVL at six-month follow-up (p = .004, McNemar's) (15). In a more recent analysis, investigators determined that of 40 participants who received Client Centered rep payee, 82% had suppressed viral loads at both 6- and 12-months follow up. The Open Door, Inc. (TOD), the organization that developed this intervention, has provided these services to 76 PLWHA over the past nine years. Though clients can terminate the rep payee arrangement at any time, 90% of clients has kept TOD as their rep payee indefinitely, demonstrating both the feasibility and acceptability of this approach. The hypothesis is that by helping clients to pay their rent and other bills on time, housing stability improves and financial stress decreases. By reducing the cognitive burden of living with chronic financial stress and frequent threats of housing loss, clients can devote more time and attention to medical appointments and medication adherence. Ultimately, it is believed that this program improves clients' self-efficacy for health behaviors, retention in care, medication adherence, CD4 counts, and viral loads. These these hypotheses will be tested via the following aims in a randomized controlled trial of 320 PLWHA.
Aim 1. Conduct a randomized controlled trial (RCT, n=160) with two additional non-randomized arms (n=50) to test the effect of Client-Centered Rep Payee on anti-retroviral (ART) medication adherence and viral load among PLWHA who are economically disadvantaged and unstably housed. Compare clinical adherence will be assessed through behavioral and biological measures including, self-reported appointment adherence, and viral load for patients receiving the intervention versus those receiving standard of care.
Aim 2. Test underlying mechanisms associated with Client-Centered Rep Payee that contribute to changes in medication adherence and viral suppression rates. Quantitative (mediation analysis) and qualitative (semi-structured interview) methods will be used to test hypothesized mediators of medication adherence and viral suppression including financial and housing instability, financial stress, self-efficacy for health behaviors, and retention in care.
Aim 3. Assess the cost and cost-effectiveness of the Client-Centered Rep Payee model. The investigators will conduct an economic analysis to model the impact of the intervention as compared with standard of care on quality adjusted life years as well as new infections averted.
Client-Centered Rep Payee offers a structural intervention to improve adherence by addressing economic insecurity. This approach requires low financial investment and can be layered with existing clinical services. Further, it is highly scalable as it builds on a current policy in practice within the Social Security system. It is projected that by demonstrating the impact and cost-effectiveness of Client-Centered Rep Payee an innovative approach to improving viral suppression rates and reducing health disparities among marginalized PLWHA may be documented.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Birmingham AIDS Outreach
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Action Wellness
-
Pittsburgh, Pennsylvania, United States, 15233
- The Open Door, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Living with HIV/AIDS
- 18 years of age and older
- English- or Spanish-speaking
- Recipient of Social Security entitlements (SSI and/or SSDI)
- Income below 138% of the federal poverty level
- One or more of the following: Not virally suppressed (viral suppression is denoted at 200 copies/ml); Unsustained viral suppression over the past 12 months; Poor ART adherence. Poor ART adherence is assessed via a CASE Index Score ≤10 or via a single question to assess the percentages of missed doses in the past week <90%. (New clients who do not have historical viral load data but are not suppressed at baseline will be eligible for the study if they meet other criteria.)
- Able and willing to provide informed consent
Exclusion Criteria:
- Currently receiving Representative Payee services or having received them in the past 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RCT: Intervention
Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
|
CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money.
By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors.
Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression.
CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
|
No Intervention: RCT: Control
Participants in the RCT control group will receive the standard of care.
|
|
Experimental: Choice Intervention
Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care.
They will not be randomly assigned.
|
CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money.
By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors.
Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression.
CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
|
No Intervention: Choice Control
Participants in the RCT control group will receive the standard of care.
They will not be randomly assigned.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in ART Adherence
Time Frame: Baseline, 12-months
|
Change in ART adherence will be calculated by comparing HIV viral load counts at Baseline versus 12 months.
|
Baseline, 12-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence of change in ART Adherence
Time Frame: Baseline plus 12 months versus Baseline plus 24 months.
|
Persistence of change in ART adherence will be calculated by comparing HIV viral load counts at 12 versus 24 months.
|
Baseline plus 12 months versus Baseline plus 24 months.
|
ART Adherence
Time Frame: Self-report of ART adherence will be measured at Baseline, 6-, and 12-months.
|
Self-report of ART adherence will be measured via the CASE adherence index, which captures self-reported missed doses of medicine.
|
Self-report of ART adherence will be measured at Baseline, 6-, and 12-months.
|
CD4
Time Frame: CD4 will be collected at Baseline, 6-, 12-, 18-, and 24- months.
|
CD4 counts will be used to assess immune system functioning.
|
CD4 will be collected at Baseline, 6-, 12-, 18-, and 24- months.
|
Self-efficacy for Adherence
Time Frame: Self-efficacy for adherence will be measured at Baseline, 6-, and 12-months.
|
Self-efficacy for adherence assess the participants' perception that they can take their medications as prescribed even in times of duress.
This will be measured via HIV-ASES, (Johnson, 2007), a 12-item scale designed to assess self-efficacy for taking HIV medications
|
Self-efficacy for adherence will be measured at Baseline, 6-, and 12-months.
|
Retention in Care
Time Frame: Retention in Care will be measured at Baseline, 6-, and 12-months.
|
Retention in Care assess the number of missed versus total scheduled visits.
Retention is defined by having at least one primary care visit per quarter or two kept visits separated by ≥ 90 days.
|
Retention in Care will be measured at Baseline, 6-, and 12-months.
|
Health-Related Quality of Life
Time Frame: Health-Related Quality of Life will be measured at Baseline, 6-, and 12-months.
|
Quality of Life related to health will be measured by a single Item General Health Measure (SF-12; DiSalvo, 2006), which is, "In general, would you say your health is: (Excellent, Very good, Good, Fair, Poor)."
|
Health-Related Quality of Life will be measured at Baseline, 6-, and 12-months.
|
Self-report of Financial Stress
Time Frame: Self-report of financial stress will be measured at Baseline, 6-, and 12-months.
|
This measure assesses the participant's self-report of stress related to financial challenges such as late payments, growing debt, etc.
It will be assessed via the Financial measures from Background Stress Inventory (Terrill, 2015).
|
Self-report of financial stress will be measured at Baseline, 6-, and 12-months.
|
Social Support
Time Frame: Social support will be measured at Baseline, 6-, and 12-months.
|
Emotional, informational and tangible functional forms of social support will be measured via the Medical Outcomes Study Social Support Survey (MOS-SSS).
|
Social support will be measured at Baseline, 6-, and 12-months.
|
Housing Status I
Time Frame: Housing status I will be measured at Baseline, 6-, and 12-months.
|
Participants' self-reported housing status will be measured via a single item question "Which best describes your current living situation?"
(Stably Housed/Unstably House/Homeless) as found in Wolitski, et.
al., 2010.
|
Housing status I will be measured at Baseline, 6-, and 12-months.
|
Housing Status II
Time Frame: Housing Status II will be measured at Baseline, 6-, and 12-months.
|
A second measure of housing status, newly developed by the study team, will be assessed via the following two questions: "In the past 90 days, have you (1) Received an eviction notice or notice to vacate because your rent was not paid?
(2) Had your utilities shutoff because your bill was not paid?"
|
Housing Status II will be measured at Baseline, 6-, and 12-months.
|
Experiences of Payeeship
Time Frame: Experiences of Payeeship will be measured at Baseline, 6-, and 12-months.
|
A 17-item questionnaire with 4 subscales will be used to assess participants (a) Satisfaction with payee/case manager, (b) Involvement of beneficiary in money management, (c) Perceived benefit from payee arrangement, and (d) feeling coerced.
These questions have been modified from a previous study (Rosen et.
al., 2005).
|
Experiences of Payeeship will be measured at Baseline, 6-, and 12-months.
|
Substance Use
Time Frame: Substance use behaviors will be measured at Baseline, 6-, and 12-months.
|
Changes in substance use behaviors will be measured via the Risk Assessment Battery (Metzger, et.a., 1993).
|
Substance use behaviors will be measured at Baseline, 6-, and 12-months.
|
Sexual Risk
Time Frame: Sexual Risk will be assessed at Baseline, 6-, and 12-months.
|
Sexual risk behaviors will be assessed to determine the likelihood of infecting others with HIV.
This will be measured via the Risk Assessment Battery (Metzger, et.a., 1993).
|
Sexual Risk will be assessed at Baseline, 6-, and 12-months.
|
Depressive Symptoms
Time Frame: Depressive Symptoms will be measured at Baseline, 6-, and 12-months.
|
Individuals experience of depressive symptoms will be measured via the Quick Inventory of Depressive Symptomology (Rush, et.al., 2003).
|
Depressive Symptoms will be measured at Baseline, 6-, and 12-months.
|
Connections with Providers
Time Frame: Connections with Providers will be measured at Baseline, 6-, and 12-months.
|
The Health Care Relationship Trust Scale will be used to assess the patient-provider relationship; i.e., discussion options, committed to best care, interested in me as a person, excellent listener, accepts me, tells me complete truth, trusts me as an individual, makes me feel I am worthy of his/her time, takes time to listen, comfort talking about personal issues, feel better after seeing healthcare provider (Bova, 2012).
|
Connections with Providers will be measured at Baseline, 6-, and 12-months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mary E Hawk, DrPH, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- STUDY20110364
- 1R01MH112416-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusSpain, France, Germany
Clinical Trials on Client-Centered Representative Payee
-
Saglik Bilimleri UniversitesiCompletedArthritis KneeTurkey
-
University of Maryland, BaltimoreNational Institute of Mental Health (NIMH); Albert Einstein College of Medicine and other collaboratorsNot yet recruitingHIV Prevention | HIV Pre-exposure Prophylaxis
-
Karolinska InstitutetThe Swedish Research Council; Region Stockholm; Swedish Council for Working Life... and other collaboratorsCompletedStroke | Multiple Disability | Physical DisabilitySweden
-
University of PittsburghNational Institute of Mental Health (NIMH)CompletedGeneralized Anxiety Disorder | Social Phobia | Separation Anxiety DisorderUnited States
-
University of PennsylvaniaCompleted
-
University of PittsburghCompletedDepressive DisordersUnited States
-
Saglik Bilimleri UniversitesiCompletedHip OsteoarthritisTurkey
-
University of Wisconsin, MadisonNational Institute on Drug Abuse (NIDA); Tulane UniversityCompletedHepatitis C | Harm Reduction | Opioid-use Disorder | Drug Use DisordersUnited States
-
Universiti Putra MalaysiaCompleted
-
Centers for Disease Control and PreventionColorado Department of Public Health and Environment; San Francisco Department... and other collaboratorsCompletedSexually Transmitted Diseases | HIV